Abstracts tagged "hyperuricemia"

Abstract Number: 366 • 2019 ACR/ARP Annual Meeting
Serum Uric Acid Level and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals: An Observational Cohort Study
Doo-Ho Lim¹, Gyung-Min Park ², Seung Won Choi ³, Su Jin Choi ⁴, So Hye Nam ⁵, Seokchan Hong ⁴, Yong-Gil Kim ⁴, Chang-Keun Lee ⁴ and Bin Yoo ⁴, ¹Division of Rheumatology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, Republic of Korea, ²Ulsan University hospital, Ulsan, Republic of Korea, ³Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea, Ulsan, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, ⁵Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: High serum uric acid (SUA) level is the main prerequisite for gout, and it might be associated with obesity, hypertension, glucose intolerance, insulin resistance,…
Abstract Number: 1215 • 2019 ACR/ARP Annual Meeting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia
Yanwei Lin¹, Xiaoxiang Chen ², Ping Ye ¹, Wenqin Geng ¹, Rui Ning ³, Yanfei Tai ³ and Chunde Bao ⁴, ¹Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, China (People's Republic), ³Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Hyperuricemia, a common metabolic disorder, predisposes patients to develop gout due to the deposition of insoluble urate in joints. Safety concerns are frequently raised…
Abstract Number: 1219 • 2019 ACR/ARP Annual Meeting
Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population
‪Gabriel Breuer‬‏¹, Marwan Abu Sneineh‬‏ ¹ and Gideon Nesher ¹, ¹Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
Background/Purpose: Hyperuricemia is associated with the development, progression and outcome of several diseases. The purpose of this study is to evaluate the serum uric acid…
Abstract Number: 1221 • 2019 ACR/ARP Annual Meeting
Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Mats Dehlin¹, Andreas Fasth ², Maximilian Reinhardt ³ and Lennart Jacobsson ⁴, ¹Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, ²Medical Affairs, Novartis Sverige AB, Kista, Sweden, Stockholm, Sweden, ³Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Germany, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden
Background/Purpose: Increased serum uric acid (sUA), hyperuricemia, has been reported to be associated with psoriasis (1). Increased cell turnover in psoriatic skin lesions has been…
Abstract Number: 1223 • 2019 ACR/ARP Annual Meeting
Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia
Danica Grujic¹, Kateryna Pirzynowska ², Paulina Szczurek ³, Stefan Pierzynowski ², Aditi Desphande ⁴, Olha Drahanchuck ⁵, Nadia Mosiichuk ⁶ and Jarek Wolinski ⁷, ¹Allena Pharmaceuticals, Boston, ²Lund University, Anara AB,/SGPlus, Lund, Sweden, ³National Research Institute of Animal Production, Vitanano Sp. z o.o./PROF,, Balice, Poland, ⁴Allena Pharmaceuticals, Newton, MA, ⁵Polish Academy of Sciences, Vitanano Sp. z o.o./PROF,, Jablonna, Poland, ⁶Lund University, Lund, Sweden, ⁷Polish Academy of Sciences, Vitanano Sp. z o.o./PROF, Jablonna, Poland
Background/Purpose: Uric acid homeostasis is determined as a balance between production, intestinal secretion and renal excretion. Around 2/3 of uric acid is excreted by the…
Abstract Number: 1229 • 2019 ACR/ARP Annual Meeting
AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial
zancong shen ¹, Elizabeth Polvent ², Vijay Hingorani ³, Shunqi Yan ⁴, Rongzi Yan ⁴ and Litain Yeh⁴, ¹Arthrosi Therapeutics, San Diego, CA, ²Arthrosi Therapeutics, Laguna Hills, CA, ³Arthrosi Therapeutics, San Diego, ⁴Arthrosi Therapeutics, Laguna Hills
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. A Phase 1…
Abstract Number: 1233 • 2019 ACR/ARP Annual Meeting
Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout
Blanka Stiburkova¹, Yu Toyoda ², Katerina Pavelcova ³, Martin Klein ⁴, Tappei Takada ² and Hiroshi Suzuki ², ¹Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic, ²Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, ³Institute of Rheumatology; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…
Abstract Number: 1270 • 2018 ACR/ARHP Annual Meeting
Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
Sharon Dowell¹, Gail S. Kerr², Alvin F. Wells³, Richard Haddad⁴, Paul DeMarco⁵, Joyce Joseph⁶, Mercedes Quinones⁷, Shelby Hochberg⁸, Jennifer Ude⁹, Jim Huang¹⁰ and David Nashel⁶, ¹Division of Rheumatology, Howard University, Washington, DC, ²Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ³Rheumatology and Immunotherapy Center, Franklin, WI, ⁴The Hospital for Special Surgery, New York, New York, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center, Washington, DC, ⁷Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center and Howard University, Washington, DC, ⁸Washington DC VA Medical Center and Howard University, Washinton, DC, ⁹Washington DC VA Medical Center and Howard University, Washington, DC, ¹⁰Medstar Health Research Institute, Hyattsville, MD
Background/Purpose: Hyperuricemia is common, and along with other comorbidities (CM), is increasing in prevalence. Though often asymptomatic, it is associated with subclinical urate deposition detectable…
Abstract Number: 1299 • 2018 ACR/ARHP Annual Meeting
A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice
Danica Grujic¹, Aditi Desphande¹, Robert Terkeltaub², Nadia Mosiichuk³, Kateryna Goncharva⁴ and Stefan Pirzynowski⁴, ¹R&D, Allena Pharmaceuticals, Newton, MA, ²VA San Diego Healthcare System, San Diego, CA, ³SGPlus and Lund University, Lund, Sweden, ⁴Lund University and SGPlus, Lund, Sweden
A novel recombinant oral urate oxidase (UrOx) ALLN-346 reduces severe hyperuricemia and normalizes hyperuricosuria in nephropathic UrOx knockout (UrOxKO) miceBackground/Purpose: Limitations in efficacy and/or tolerance…
Abstract Number: 2219 • 2018 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
Masuharu Hirano¹, Shiro Kobayashi², Eri Miyayama², Takashi Ohta¹, Masao Yamamoto² and Tomio Yamakawa³, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Development Planning Department, Nippon Chemiphar Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: Gout flare due to rapid urate reduction after initiating urate-lowering therapy (ULT) is one of the major issues in the therapy. International guidelines recommend…
Abstract Number: 2246 • 2018 ACR/ARHP Annual Meeting
Insulin: Genetic and Physiological Influences on Human Uric Acid Homeostasis
David B. Mount¹, Tony R. Merriman² and Asim Mandal¹, ¹Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²University of Otago, Dunedin, New Zealand
Background/Purpose: Insulin plays a key role in the genesis of hyperuricemia. In particular, hyperinsulinemia in metabolic syndrome is inversely correlated with urinary uric acid (UA)…
Abstract Number: 2967 • 2018 ACR/ARHP Annual Meeting
Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity
Laura Gabriela Sánchez Lozada¹, Fernando E. García-Arroyo², J. Gabriel Juárez-Rojas³, Guillermo Gonzaga² and Raymond P. Warrell Jr.⁴, ¹Nephrology, INC Ignacio Chavez, Mexico City, Mexico, ²INC Ignacio Chavez, Mexico City, Mexico, ³INC Ignacio Chavez, Mexoci City, Mexico, ⁴Relburn-Metabolomics, Inc., Westfield, NJ
Background/Purpose: Dietary fructose promotes an increase in uric acid (UA) that may lead to gout. UA itself promotes lipogenesis and inflammation in both gout as…
Abstract Number: 1125 • 2018 ACR/ARHP Annual Meeting
Association between Hyperuricemia and Metabolic Syndrome with or without Obesity: Results from the 2016 Korea National Health and Nutrition Examination Survey
In Young Kim¹, Yeong Hee Eun¹, Eun-Jung Park², Joong Kyong Ahn³, Chan Hong Jeon⁴, Jaejoon Lee⁵, Hoon-Suk Cha¹, Eun-Mi Koh⁵, Kyungdo Han⁶ and Hyungjin Kim¹, ¹Department of Medicine, Division of Rheumatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine, Division of Rheumatology, National Medical Center, Seoul, Korea, Republic of (South), ³Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ⁴Department of Medicine, Division of Rheumatology, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), ⁵Department of Medicine,Division of Rheumatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ⁶Department of Biostatistics, Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Hyperuricemia is increasing worldwide, and is emerging as a potential biomarker and predictor for metabolic syndrome and related complications. We aimed this study to…
Abstract Number: 170 • 2017 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Ascertained Gout and Subtypes Identifies Multiple Susceptibility Loci Including Transporter Genes
Hirotaka Matsuo¹, Akiyoshi Nakayama², Hirofumi Nakaoka³, Ken Yamamoto⁴, Masayuki Sakiyama⁵, Amara Shaukat⁶, Yu Toyoda⁷, Yukinori Okada⁸, Yoichiro Kamatani⁹, Masahiro Nakatochi¹⁰, Takahiro Nakamura⁵, Tappei Takada⁷, Hiroshi Nakashima⁵, Seiko Shimizu⁵, Makoto Kawaguchi⁵, Asahi Hishida¹¹, Kenji Wakai¹¹, Blanka Stiburkova¹², Karel Pavelka¹³, Lisa K. Stamp¹⁴, Nicola Dalbeth¹⁵, Tatsuo Hosoya¹⁶, Michiaki Kubo⁹, Hiroshi Ooyama¹⁷, Toru Shimizu¹⁸, Kimiyoshi Ichida¹⁹, Tony R. Merriman²⁰ and Nariyoshi Shinomiya²¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Dept Integrative Physiol, National Defense Med College, Tokorozawa, Japan, ³National Inst Genet, Mishima, Japan, ⁴Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ⁵National Defense Med College, Tokorozawa, Japan, ⁶Univ Otago, Dunedin, New Zealand, ⁷Univ Tokyo Hosp, Tokyo, Japan, ⁸Osaka University, Osaka, Japan, ⁹Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ¹⁰Nagoya Univ Hosp, Nagoya, Japan, ¹¹Nagoya Univ Grad Sch Med, Nagoya, Japan, ¹²Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Rheumatology, Prague, Czech Republic, ¹⁴University of Otago, Christchurch, New Zealand, ¹⁵University of Auckland, Auckland, New Zealand, ¹⁶Jikei Univ Sch Med, Tokyo, Japan, ¹⁷Ryougoku East Gate Clin, Tokyo, Japan, ¹⁸Kyoto Industr Health Assoc, Kyoto, Japan, ¹⁹Tokyo Univ Pharmacy Life Sci, Tokyo, Japan, ²⁰Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²¹National Defense Med College, Saitama, Japan
Background/Purpose: We performed a genome-wide association study (GWAS) of gout and its subtypes to identify novel gout loci including those that are subtype-specific. Methods: Putative…
Abstract Number: 672 • 2017 ACR/ARHP Annual Meeting
Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Doo-Ho Lim¹, Seokchan Hong², Ji Seon Oh³, Yong-Gil Kim², Chang Keun Lee², Seung Won Choi¹ and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, National Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Although lupus nephritis is a common and serious manifestation of SLE, there have been few predictive markers for development of lupus nephritis in SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].